UPDATE: Cowen Reiterates $150 PT on Novavax (NVAX), Believes 'briefing documents suggest that the vaccine meets all the requirements for approval '

Novavax (NVAX) Shares Halted for News Pending Ahead of FDA Panel

June 7, 2022 6:55 AM EDT

Novavax (NASDAQ: NVAX) Shares Halted for News Pending Ahead of FDA Panel

... More

Why Novavax (NVAX) Stock Price is Trading Sharply Lower Today

June 3, 2022 9:32 AM EDT

Shares of Novavax (NASDAQ: NVAX) are down more than 13% today after the U.S. Food and Drug Administration (FDA) released briefing documents concerning the companys COVID-19 vaccine.

The FDAs staff said today that the companys vaccine reduces the risk of... More

Novavax (NVAX) falls 9% following FDA briefing documents

June 3, 2022 9:23 AM EDT

Novavax (NASDAQ: NVAX) falls 9% following FDA briefing documents.

... More

Pre-Open Stock Movers 06/03: Turning Point Doubles on Takeover; Tesla Falls as Musk Worried About Economy, Cutting 10% of Staff

June 3, 2022 9:10 AM EDT

Pre-Open Stock Movers:

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) 117% HIGHER; Bristol Myers Squibb (NYSE: BMY) and Turning Point Therapeutics, Inc. (NASDAQ: TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share.

JOANN Inc (NASDAQ: JOAN) 17% LOWER; reported Q1 EPS of ($0.22), $0.32 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $498 million... More

U.S. FDA flags risk of heart inflammation after Novavax COVID vaccine

June 3, 2022 8:55 AM EDT

By Manas Mishra and Mrinalika Roy

(Reuters) -The U.S. Food and Drug Administration has raised concerns about a possible risk of heart inflammation from Novavax Inc's COVID-19 vaccine, even as the company's data showed it could reduce the chances of mild-to-severe disease.

In Novavax's nearly 30,000 patient trial, conducted between December 2020 and September 2021, there were four cases of a type of heart inflammation called myocarditis detected within 20 days of taking the protein-based shot.

"These events raise the concern for a causal association with this vaccine, similar to the association documented with mRNA COVID-19 vaccines," FDA staff... More

Novavax (NVAX) on Watch Following Briefing Docs Post

June 3, 2022 8:29 AM EDT

Novavax (NASDAQ: NVAX) on Watch Following Briefing Docs Post

... More

Moderna (MRNA) Sliding Lower as EU Postpones Additional COVID Booster Deliveries, Pfizer (PFE) and Novavax (NVAX) on Watch

June 2, 2022 6:57 AM EDT

Shares of Moderna (NASDAQ: MRNA) are trading 2% lower Thursday morning as the company announced it had agreed to amend the delivery schedule of additional COVID-19 vaccine booster shots to the European Union.

The agreement, the first public announcement of its kind, is allowing participating EU... More